Passer au contenu de la page principale

Incidence of Conjunctivitis Prior to and Following the COVID-19 Pandemic: A Population-Based Study - 5578

Mon statut pour la session

Quand:
11:45 AM, Dimanche 22 Juin 2025 (5 minutes)
Author’s Name(s): Tina Felfeli, Yvonne M Buys, Sherif El-Defrawy, Ya-Ping Jin

Author’s Disclosure Block: Tina Felfeli, none; Yvonne M Buys, none; Sherif El-Defrawy, none; Ya-Ping Jin, none

Abstract Body
Purpose:The occurrence of conjunctivitis in patients with COVID-19 has been reported to vary largely (0-31.6%) from hospital-based studies. Using population-based data, we assessed the incidence of conjunctivitis in patients with and without COVID-19 in 2020 and in general populations pre-pandemic. Study Design: Retrospective cohort. Methods: Ontario’s physician billing data from 2010-2020 were analysed. Cohort 1: Data in 2010-2019 were used to establish the conjunctivitis incidence pre-pandemic. Cohort 2: One COVID-19 individual in 2020 was matched by age, sex and urban/rural residence to 3 randomly selected non-COVID-19 individuals in 2020 and again to 3 non-COVID-19 individuals in 2019. The 2019 matched individuals wereincluded to address the concern that people might have avoided seeking eye care during the pandemic, resulting in a “false” low conjunctivitis incidence rate among non-COVID-19 individuals in 2020.In cohort 1 and 2, conjunctivitis was the study outcome and was recognized from diagnostic codes (ICD-9 and -10) billed by all physicians. In cohort 2, COVID-19 infection was the exposure and was identified using the lab confirmed COVID-19 test result from Jan 15 to Nov 30, 2020. The adjusted hazard ratio (aHR) derived from the Cox regression model was used to assess the association between COVID-19 infection and conjunctivitis risk. Variables adjusted for included age, sex, rural/urban residence, neighborhood income level, diabetes, cancer, hospitalization and ICU stay. Results: Pre-pandemic, the annual incidence of conjunctivitis varied slightly from 2.71% in 2010 to 2.16% in 2019. Higher rate was observed in people aged 0-19 (3.11%) vs other age groups (1.56-1.97% in 2019) and in females (2.28%) vs males (1.89% in 2019).In 2020, 106,713 individuals had lab-confirmed COVID-19 infection, with a mean age of 43.7 (ranging from 0-100) years and 52% females. Conjunctivitis occurred in 200 of them within 4 weeks of COVID-19 onset. The conjunctivitis incidence was 0.19% per 4 person-weeks (or 2.5% per year) in COVID-19 individuals, higher than the incidence in non-COVID-19 individuals (0.11% per 4 person-weeks, or 1.4% per year) in 2020. The aHR of conjunctivitis was 1.6 (95% confidence interval [CI] 1.4-2.0), significantly higher in individuals with vs without COVID-19.However, compared with the matched non-COVID-19 individuals selected from 2019, the conjunctivitis incidence in COVID-19 individuals was not higher: 0.19% vs 0.19% per 4 person-weeks for individuals with and without COVID-19. The aHR of conjunctivitis was 0.9 (95% CI 0.8-1.1) for individuals with vs without COVID-19. Conclusions: The risk of conjunctivitis was significantly higher in individuals with COVID-19 vs non-COVID-19 individuals selected from the pandemic period. However, this increased risk was not observed compared with non-COVID-19 individualschosen from the pre-pandemic period.

Mon statut pour la session

Évaluer

Detail de session
Pour chaque session, permet aux participants d'écrire un court texte de feedback qui sera envoyé à l'organisateur. Ce texte n'est pas envoyé aux présentateurs.
Afin de respecter les règles de gestion des données privées, cette option affiche uniquement les profils des personnes qui ont accepté de partager leur profil publiquement.

Les changements ici affecteront toutes les pages de détails des sessions